AssetID: 56099772
Headline: UNCAPTIONED: Experimental mRNA Vaccine Cuts Risk Of Melanoma Returning By 42%
Caption: Experimental mRNA Vaccine Cuts Risk Of Melanoma Returning By 42%. An experimental personalised mRNA cancer vaccine reduced the risk of melanoma returning after surgery or death by 42% in a late-stage clinical trial. The vaccine, called intismeran autogene, was developed by Merck and Moderna and was given alongside the approved cancer drug Keytruda. Patients receiving the combination had significantly better outcomes than those treated with Keytruda alone, according to results released by the companies. The vaccine uses mRNA technology similar to Moderna's Covid-19 vaccine but trains the immune system to recognise and attack cancer cells. Each vaccine is individually designed using the genetic signature of a patient's tumour after it has been surgically removed and sequenced. The treatment targets markers in the tumour most likely to trigger an immune response, allowing the body to focus its defences on individual cancer cells. Merck and Moderna said they were discussing the results with regulators, potentially paving the way for an application for U.S. approval. The technology is also being tested against other cancers, including lung and pancreatic cancer, as researchers explore its potential beyond melanoma. Instructions: THIS VIDEO MUST NOT BE EDITED FOR LENGTH TO COMBINE WITH OTHER CONTENT
Keywords: Health & Wellbeing,melanoma,mRNA vaccine,cancer vaccine,intismeran autogene,Moderna,Merck,Keytruda,cancer treatment,cancer research,immunotherapy,clinical trial,oncology,tumour,immune system
PersonInImage: